Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q3 2022 vs. Q2 2022
How the institutions holding Gain Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 16 | 23 | +7 |
| Shares | 1.08M | 1.21M | +138.4K (+12.9%) |
| Value | $3.87M | $3.95M | +$85.9K (+2.2%) |
New holders (7)
Institutions that held Gain Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wealth Alliance Advisory Group, LLC | 25,000 | $82.0K | 0.04% |
| Raymond James & Associates | 24,000 | $78.0K | 0.00% |
| Northern Trust Corp | 12,546 | $41.0K | 0.00% |
| Dimensional Fund Advisors LP | 11,942 | $39.0K | 0.00% |
| JPMorgan Chase & Co | 594 | $2.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 283 | $923 | 0.00% |
| Simplex Trading, LLC | 100 | $0 | 0.00% |
Sold out (0)
Institutions that held Gain Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
None.